Press release
Dato-DXd by AstraZeneca and Daiichi Sankyo expected to drive market size of Antibody Drug Conjugates by 2034
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Dato-DXd (AstraZeneca and Daiichi Sankyo) providing insights into the drug market landscape and market forecast of Dato-DXd upto 2034. The report, titled "Dato-DXd, Market Size, Forecast, and Emerging Insight - 2034" is now available for review and analysis.
Are you interested in finding out the projected market size of Dato-DXd in 2034? Dato-DXd Market Forecast
https://www.delveinsight.com/report-store/dato-dxd-sale-forecast-and-market-analysis [https://www.delveinsight.com/report-store/dato-dxd-sale-forecast-and-market-analysis?utm_source=abnewswire&utm_medium=druginsightpr&utm_campaign=gpr]
Key Factors Driving Dato-DXd Growth
1. Market Share Gains and New Patient Starts
*
Dato-DXd is emerging as a promising antibody-drug conjugate (ADC) in the solid tumor treatment landscape, especially for lung and breast cancers where there is a significant unmet medical need.
*
New patient initiations are expected to grow as oncologists increasingly embrace next-generation ADCs for patients whose disease has progressed after standard chemotherapy, immunotherapy, or targeted treatments.
*
Heightened interest from the oncology community is fueled by promising efficacy results in heavily pretreated patients, bolstering clinical confidence in the therapy.
*
AstraZeneca and Daiichi Sankyo's collaborative commercial and medical strategy, featuring active investigator engagement and extensive data sharing, is driving increased awareness and adoption of Dato-DXd.
2. Expansion Across Key Indications
*
Non-Small Cell Lung Cancer (NSCLC): Dato-DXd is under active development for previously treated metastatic NSCLC, targeting patients with limited treatment options following chemotherapy and immunotherapy.
*
Breast Cancer: Development is heavily focused on HR-positive/HER2-low and triple-negative breast cancer (TNBC), where ADCs are rapidly transforming treatment approaches.
*
Broader Solid Tumors: Development efforts are ongoing to target additional TROP2-expressing tumors, potentially expanding the treatable patient population.
*
Pipeline Expansion and Combination Approaches: Strategies such as combining with immune checkpoint inhibitors are anticipated to further extend the drug's market potential.
The Dato-DXd Market Report offers projected sales forecasts for Dato-DXd for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
AstraZeneca and Daiichi Sankyo's Dato-DXd is serving as a beacon of hope for the patients suffering from the Antibody Drug Conjugates.
Dato-DXd Recent Developments
*
In December 2025, The European Medicines Agency (EMA) validated the Type II Variation marketing authorization application for DATROWAY (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
*
In October 2025, Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.
What is a Dato-DXd Prescribed for?
Dato-DXd (datopotamab deruxtecan) is prescribed for the treatment of advanced or metastatic solid tumors, particularly non-small cell lung cancer (NSCLC) and breast cancer. It is an antibody-drug conjugate (ADC) that targets TROP2, a protein highly expressed on many cancer cells, delivering a potent chemotherapy payload directly to tumors. Dato-DXd is mainly intended for patients with previously treated, unresectable, or metastatic disease, especially those who have progressed after standard therapies.
The report extensively covers the details and developments related to Dato-DXd, capturing important highlights on developmental pipeline, regulatory status and special designations of Dato-DXd, route of administration, safety and efficacy details.
Do you know your drug's competitive positioning against Dato-DXd? Dato-DXd Drugs Insights [https://www.delveinsight.com/sample-request/dato-dxd-sale-forecast-and-market-analysis?utm_source=abnewswire&utm_medium=druginsightpr&utm_campaign=gpr]
Dato-DXd Market Assessment
This report provides a detailed market assessment of Dato-DXd for Antibody Drug Conjugates in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2034.
Dato-DXd Clinical Assessment
The report provides the clinical trials information of Dato-DXd for Antibody Drug Conjugates covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Dato-DXd Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Dato-DXd.
Dato-DXd Market Size in the US
A dedicated section of the report focuses on the expected market size of Dato-DXd for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
Key Highlights of Dato-DXd:
*
The report contains forecasted sales of Dato-DXd for indication till 2034.
*
Comprehensive coverage of the late-stage emerging therapies for Antibody Drug Conjugates.
*
The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Dato-DXd in Antibody Drug Conjugates.
Stay ahead in competition by leveraging insights on Dato-DXd market Report: Download the sample for Dato-DXd Market Report [https://www.delveinsight.com/sample-request/dato-dxd-sale-forecast-and-market-analysis?utm_source=abnewswire&utm_medium=druginsightpr&utm_campaign=gpr]
Why you should buy Dato-DXd Market Report:
*
The report provides future market assessments for Dato-DXd for Antibody Drug Conjugates in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
*
Leading Dato-DXd for Antibody Drug Conjugates forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Dato-DXd
*
Discover the competitive landscape of Dato-DXd through 7MM
*
Get a Thorough Analysis of the Dato-DXd Development pipeline, Safety & Efficacy of the Dato-DXd, and ROA
*
Thorough Dato-DXd market forecast will help understand how drug is competing with other emerging Dato-DXd
*
Get analysis of the Dato-DXd clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
*
Drug Market forecasts are calculated after taking into consideration KOL viewpoints
Related Reports By DelveInsight:
Antibody Drug Conjugates Pipeline
DelveInsight's, "Antibody Drug Conjugates Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/antibody-drug-conjugate-competitive-landscape?utm_source=abnewswire&utm_medium=druginsightpr&utm_campaign=gpr]" report provides comprehensive insights about 180+ companies and 290+ pipeline drugs in Antibody Drug Conjugates pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=datodxd-by-astrazeneca-and-daiichi-sankyo-expected-to-drive-market-size-of-antibody-drug-conjugates-by-2034]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dato-DXd by AstraZeneca and Daiichi Sankyo expected to drive market size of Antibody Drug Conjugates by 2034 here
News-ID: 4361922 • Views: …
More Releases from ABNewswire
Best Local San Antonio SEO Service. JCE SEO Helps Multi-Location Restaurant Bran …
Best Local San Antonio SEO Service. Driving Scalable Growth for a Multi-Location Restaurant
JCE SEO, a revenue-focused digital marketing agency, announced today the success of a multi-location restaurant client that achieved significant year-over-year growth by implementing JCE's proprietary Custom Revenue Machine.
Despite rising food and labor costs across the restaurant industry, the brand experienced 40-60% revenue growth, improved operating margins, and more predictable customer acquisition across its locations.
"Our goal wasn't just to…
ZenaTech Inc. (Nasdaq: ZENA): Leveraging Drones to Solve Labor Constraints in In …
Global infrastructure spending is accelerating. Governments and enterprises are committing record capital to transportation, energy, utilities, telecom, and public works. The challenge is execution. Surveying, inspecting, documenting, and maintaining assets is hitting its limits. Labor shortages, rising insurance costs, and stricter compliance rules make traditional fieldwork expensive and slow.
That gap is fueling demand for drone-enabled services and automated data collection. The global drone services market is expected to grow more…
Best AI Talking Photo Tools for 2026: How to Choose the Right Tool
This guide compares leading AI talking photo tools that animate still images into speaking videos. It evaluates Magic Hour, CapCut, Synthesia, and D-ID across lip sync accuracy, facial animation quality, speed, consistency, language support, and production readiness, with clear "best for" recommendations across common workflows.
AI talking photo tools vary widely in what they optimize for. Some prioritize fast, social-ready outputs, others focus on expressive avatars or enterprise communication, while some…
UK SEO Summit Announces Hybrid SEO Conference Taking Place on 26 August in Londo …
London, UK - The UK SEO Summit [https://www.ukseosummit.com/] has officially announced its upcoming edition, scheduled for 26 August in London, positioning itself as one of the most anticipated SEO events UK for professionals navigating today's rapidly evolving search landscape. Designed as a hybrid event, the summit enables both in-person and online participation, ensuring global accessibility while maintaining a strong on-ground presence in the UK capital.
Recognised as a leading SEO conference…
More Releases for Drug
Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming…
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage
Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic…
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:
* Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
* Global and Regional Antibody Drug Conjugate Market Insight
* Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
* Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
* Insight On Antibody Drug Conjugates In Clinical Trials: > 550…
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
